China Biologic Products Holdings Inc

China Biologic Products — Investor Presentation (June 2011)

28 slides from China Biologic Products's investor presentation, Jun 7, 2011

  1. Slide 1: China Biologic Products, Inc. - June 2011

    June 2011 ’, China Biologic Products, Inc. A profitable, rapidly growing plasma-based biopharmaceutical products company in China

  2. Slide 2: Cautionary Statement Regarding Forward-looking statements

    Cautionary Statement Regarding Forward-looking statements This presentation includes or incorporates by reference statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,

  3. Slide 3: Company Overview

    @ Company Overview Aleading independent plasma company in China * Operations in 3 provinces with a combined population of over 160 million people Shandong Taibang Biological Products Co., Ltd. + Top ranked player in the $1B market for plasma-based products in China (83% controlling ownership) + Dyna

  4. Slide 4: Manufacturing

    Manufacturing (Fractionation) Indirect ownership in 3 out of 32 approved sites in China products are sold Plasma Collection to hospitals and 17 plasma collection inoculation centers in operation out of i ‘¢€ clinics in China an estimated 140 in China; Broad-based plasma derived 2centers currently un

  5. Slide 5: Investment Highlights

    @ ®@ Investment Highlights = ——— Blood products are critical and cannot be substituted in the treatment of medical emergencies and some potentially life-threatening diseases Total Sales US$ in millions « Demand exceeds supply. 160 « Tight government regulations create favorable conditions for leadin

  6. Slide 6: Government Reform of Plasma-based Industry

    Government Reform of Plasma-based Industry + Reform of plasma collection stations in 2006 * GMP Certification required for plasma collection stations and biopharmaceutical manufacturers + Restriction of imported products due to past outbreaks + Limited allowance of new collection stations / No new p

  7. Slide 7: Plasma Collection

    Plasma Collection Rapid Decline in Total Collected Plasma in China Due to Government Instituted Reforms 2005 2010 5,000 metric tons 4,000 est. metric tons Collected Collected Collected Collected plasma by Plasmaby plasma in plasma in ‘Shandong Shandong ‘China by China by Taibang & Guizhou others oth

  8. Slide 8: What is Plasma?

    What is Plasma? Plasma Collection o- a) q Centrifugation rocess to separate plasma Rest of Blood Albumin Plasma Freeze (-30°C) Others China Biologic Products, Inc. 8

  9. Slide 9: Growing Market Opportunity

    Growing Market Opportunity « Rapid expansion in China’s pharmaceutical market « Pharmaceutical market expected to grow at 20%+ pace annually through 2013 (ims Health, Oct 2009). « Drivers include higher health standards, aging population, government spending, rising disposable incomes and accelerati

  10. Slide 10: Stringent Quality Control

    ® Stringent Quality Control a — Shandong Taibang is one of first plasma-based manufacturers in China to receive GMP certification (1999); renewed in 2008 + High barrier to entry: as of 1999, GMP certification is no longer granted to new blood products manufacturers. + Stricter inspection standards i

  11. Slide 11: Product Sales Mix

    Product Sales Mix ———s Increasing product diversification and growth in higher margin products % of of PRODUCTS 2010 192011 Sales! Sales! 48.0% 57.2% 34.3% 30.2% 5.3% 2.2% 2.9% 3.4% inoglob 0.7% 0.0% 7.6% 6.4% 1.2% 0.6% 1. Includes Shandong and Guizhou Taibang and excludes Huitian. logic Products, I

  12. Slide 12: Estimated IVIG Market Share in China

    Estimated IVIG CBPO Market Share in China (Jan '11) market share based on output volume: 15% = Restofthe Market ™ Guizhou Taibang = Huitian ™ Shandong Taibang ‘Source: National institute for the Control of Pharmaceutical and Biological Products. Guizhou Xian Taibang | Huitian’ Plasma collection 3 ce

  13. Slide 13: Registration, Filing and Commercialization

    Registration, Filing and ‘Commercialization Human Prothrombin Complex Concentrate 2011 2011 Products Preclinical Phase | Phase ll Phase III Human Coagulation Factor Vill EE Human Hepatitis B Immunoglobulin (PH 4) | gues for Intravenous Injection Human Fibrinogen 1 Varicella Hyperimmune Globulins a H

  14. Slide 14: New Product Pipeline

    @ @ New Product Pipeline Products Development Status Human Prothrombin Complex Concentrate Approved to commence clinical trial (stage 9) Commercial production expected in 1H 2011 Human Coagulation Factor Vill Approved to commence clinical trial (stage 9) Commercial production expected in IH 2011 Hum

  15. Slide 15: On-going R&D Objectives

    On-going R&D Objectives ¥ Expand portfolio of plasma-based biopharmaceutical products Y Maximize manufacturing efficiency and safety Y Promote product safety by implementing new technologies v Refine production technology for existing products & China Biologic Products, Inc. 45 Ke 5 se ee

  16. Slide 16: Management Profiles

    Management Profiles —_— Mr. Chao ig Zhao, CEO of China Biologic Products * More than 10 years of experience in finance, accounting, and internal control. * Certified Accountant in PRC and an intemational registered internal auditor. * MBA in Finance from Chinese University of Hong Kong Mr. Stanley L

  17. Slide 17: A profitable, rapidly growing plasma-based biopharmaceutical products company in China

    & ’, China Biologic Products, Inc. A profitable, rapidly growing plasma-based biopharmaceutical products company in China

  18. Slide 18: Strong Sales Growth

    Strong Sales Growth 2007 2008 2009 2010 1Q 2010 1Q 2011 % , Q 3 % — : & China Biologic Products, Inc. 48

  19. Slide 19: Attractive Gross Margin

    @ Attractive Gross Margin 1 102.7 ' 100 ! 4 ! 80 ! 1 1 60 ! win? ore i} yor Gro ° ! a i 25.2 1 20.3 20 1 6 L 2005 2006 2007 2008 2009 2010 ' 1Q 2010 1Q 2011 China Biologic Products, Inc. 49 Sse ee

  20. Slide 20: Rising Net Income

    @ Rising Net Income 2009 2010 | 12010 102011 EPs’ % $0.29 $0. a. Based on the adjusted Non-GAAP net income as described in detail on slide 21. For the most recent periods, please also see the GAAP and Non-GAAP reconciliation table on slide 28. C China Biologic Products, Inc. 20

  21. Slide 21: Financial summary ($ in millions)

    ($ in millions) 2011 2010 2010 2009 2008 2007 $32.7 $22.5 Gross Profit $25.2 Operating Income $14.5 $13.2 $69.5 $61.4 $20.3 $12.8 Adjusted Net Income $8.0 $7.6" $39.0° $31.54 $13.3° $8.2 eo, © 2 China Biologic Products, Inc. 21

  22. Slide 22: Selected Balance Sheet

    = @ Selected Balance Sheet = ——— Cash and cash equivalents 56.3 64.9 Total Current Assets 133.9 132.8 Total Current Liabilities 74.0 71.4 Total Shareholders’ Equity 143.9 84.1 © 2 China Biologic Products, Inc. 22

  23. Slide 23: Peer Valuation Comparison

    @ Reer Valuation Comparison ——<—<—_—_—_$—$$— Hualan Biological Engineering 002007.s2 cNY33.64 CNY 1,262 CNY 4.08 Bejing Tiantan Biological Products 60016138 cNy 17.20 CNY 1,193 CNY 0.35 Shanghai RAAS Blood Products 002252.s2 CNY 25.33 Ny 483 ony 0.68 CSL Li CSL-AU AUD 34.10 AUD 4,456 43x AUD1.88 20.

  24. Slide 24: Future Growth Strategies

    Futare Growth Strategies « Increase plasma collection through organic growth and acquisitions « Increase yields on existing products through investments and facilities, R&D and process modifications and upgrades « Broaden product portfolio through R&D investments and collaborations « Future acquisit

  25. Slide 25: China Biologic Products Inc.

    China Biologic Products Inc. Y. Tristan Kuo, CFO No.14 East Hushan Road Taian City, Shandong 271000 PRC Beijing +86 53 8620 2306 [email protected] Legal Counsel Pillsbury Winthrop Shaw Pittman LLP Christensen Kimberly Minarovich, Managing Director New York +1 212 618 1978 kminarovich@christenseni

  26. Slide 26: Appendix: SFDA Approval Process

    @ ppendix: SFDA Approval Process Overview of SFDA Approval Process for New Plasma Products Stage Est. Time (Months) 1 Planning stage 1 2 Feasibility study and assumption clarification 2 3 Develop scope and technique for testing the new medicine 6 4 Preparation of a virus inactivation report and subm

  27. Slide 27: Reconciliation of Non-GAAP Financial Measures

    CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP FINANCIAL MEASURES FOR THE THREE MONTHS ENDED MARCH 31, 2011 AND 2010 AND YEAR ENDED DECEMBER 31,2010 AND 2009 [Adjusted net income attributable to China [Biologic -Non GAAP $ 7.965.191 $ 031 $ 7.574.186 o2e| |s_saser.447 1.81

  28. Slide 28: China Biologic Products, Inc. - June 2011

    June 2011 & ’, China Biologic Products, Inc. A profitable, rapidly growing plasma-based biopharmaceutical products company in China

China Biologic Products — Investor Presentation (June 2011) on 6ix